Fate Therapeutics (FATE) Income from Non-Controlling Interests (2016 - 2026)
Fate Therapeutics (FATE) posted Income from Non-Controlling Interests of -$193000.0 for Q1 2026, down 421.62% on a QoQ basis from -$37000.0 in Q4 2025, and down 150.65% year-over-year from $381051.3 in Q1 2025.
Fate Therapeutics (FATE) Income from Non-Controlling Interests (2016 - 2026) Analysis & Trends
Fate Therapeutics' Income from Non-Controlling Interests history runs 11 years deep, the most recent figure standing at -$193000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 150.65% year-over-year to -$193000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$268000.0 (down 169.61% YoY) and the FY2025 annual result came in at -$152000.0, down 160.08% from the prior year.
- Income from Non-Controlling Interests was -$193000.0 for Q1 2026 at Fate Therapeutics, down from -$37000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.4 million in Q4 2022 and bottomed at -$2.1 million in Q1 2022.
- A 5-year average of $40294.1 and a median of -$37000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests tumbled 532.73% — and 2024, when it jumped 1328.41%.
- Fate Therapeutics' Income from Non-Controlling Interests stood at $1.4 million in 2022, then slumped by 63.26% to $514000.0 in 2023, then slumped by 210.31% to -$567000.0 in 2024, then soared by 93.47% to -$37000.0 in 2025, then sank by 421.62% to -$193000.0 in 2026.
- Business Quant data shows FATE's Income from Non-Controlling Interests at -$193000.0 in Q1 2026, -$37000.0 in Q4 2025, and $91000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - | -193,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -193,000.00 |
| Dec 31, 2025 | -37,000.00 |
| Sep 30, 2025 | 91,000.00 |
| Jun 30, 2025 | -129,000.00 |
| Mar 31, 2025 | -77,000.00 |
| Dec 31, 2024 | -567,000.00 |
| Sep 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | -228,000.00 |
| Mar 31, 2024 | -209,000.00 |
| Dec 31, 2023 | 514,000.00 |
| Sep 30, 2023 | 88,000.00 |
| Jun 30, 2023 | 59,000.00 |
| Mar 31, 2023 | 1.21 Mn |
| Dec 31, 2022 | 1.40 Mn |
| Sep 30, 2022 | 128,000.00 |
| Jun 30, 2022 | -531,000.00 |
| Mar 31, 2022 | -2.09 Mn |
| Dec 31, 2021 | -689,000.00 |
| Sep 30, 2021 | 13,000.00 |
| Jun 30, 2021 | 174,000.00 |